Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.66 |
| ▸ | GABRP | O00591 | 1/20 | 0.64 |
| ▸ | GABRD | O14764 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | KLK3 | P07288 | 1/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.64 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.64 |
| ▸ | GABRE | P78334 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31071654 | 1.00 | AR (0.71) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL31174862 | 0.92 | AR (0.67) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL22117719 | 0.92 | AR (0.67) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL7035063 | 0.89 | AR (0.87) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL15506447 | 0.89 | ABCG2 (0.77) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL30431957 | 0.89 | ABCG2 (0.77) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL22117941 | 0.88 | AR (0.72) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL22117774 | 0.88 | AR (0.72) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL31174822 | 0.88 | AR (0.72) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL31174824 | 0.88 | AR (0.72) | ARABCG2GABRPGABRDNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240368083-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2024-11-07 | — | — | US | disclosed |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2023-01-05 | — | — | US | disclosed |
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3897636-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Celgene Corporation (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897635-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Celgene Corporation (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11149007-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2021-10-19 | — | — | US | disclosed |
| WO-2020132016-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132014-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-06-25 | — | — | US | disclosed |
| US-20200199074-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | AR 1/4885ABCG2 3495/4885GABRP 1778/4885 |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | AR 1/4885ABCG2 3495/4885GABRP 1778/4885 |
| US-20240368083-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | AR 1/4885ABCG2 3495/4885GABRP 1778/4885 |
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | AR 1/4885ABCG2 3723/4885GABRP 1741/4885 |
| US-11149007-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | AR 1/4885ABCG2 3495/4885GABRP 1778/4885 |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | AR 1/4885ABCG2 3495/4885GABRP 1778/4885 |
| US-20200199074-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | AR 1/4885ABCG2 3723/4885GABRP 1741/4885 |
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | AR 1/4885ABCG2 3495/4885GABRP 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.